Related Experiment Videos
A randomized study of carbamazepine versus no medication after a first unprovoked seizure in childhood
P Camfield1, C Camfield, J Dooley
1Department of Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada.
Insights
Carbamazepine (CBZ) reduced seizure recurrence in children after a first unprovoked seizure. However, side effects and febrile seizures limited its benefit for some, impacting the goal of a seizure-free year.
Area of Science:
- Pediatric Neurology
- Clinical Pharmacology
Background:
- Epilepsy management in children requires careful consideration of treatment efficacy and tolerability.
- Recurrence risk after a first unprovoked seizure influences treatment decisions.
Purpose of the Study:
- To evaluate the efficacy and tolerability of carbamazepine (CBZ) in preventing seizure recurrence in children after a first afebrile unprovoked seizure.
Main Methods:
- A randomized trial involving 31 children with a first afebrile unprovoked seizure.
- Participants were assigned to receive carbamazepine (CBZ) or no medication for one year or until a second seizure.
- Seizure types included focal onset and generalized tonic-clonic seizures.
Main Results:
- 2 out of 14 children on CBZ experienced recurrent afebrile seizures, compared to 9 out of 17 in the no-medication group.
- Four children discontinued CBZ due to side effects, and two experienced febrile seizures while on CBZ.
- Only 6 out of 14 children on CBZ achieved a completely seizure-free year without unacceptable side effects.
Conclusions:
- Carbamazepine (CBZ) significantly reduces seizure recurrence after a first afebrile unprovoked seizure in children.
- Side effects and the occurrence of febrile seizures may limit the overall benefit of CBZ for some pediatric patients.
- Treatment decisions should weigh the benefits of seizure reduction against potential adverse effects and recurrences.
Abstract:
We randomized 31 children with a 1st afebrile unprovoked seizure to receive carbamazepine (CBZ) or no medication for 1 year or until the time of a 2nd seizure. All seizures had a focal onset or were generalized tonic-clonic. Overall, 2/14 randomized to CBZ and 9/17 with no medication had a recurrent afebrile seizure. Compliance with CBZ was excellent in 12/14, but noncompliance may have contributed to 1 of the recurrences with CBZ. Four discontinued CBZ because of side effects. Two additional children taking CBZ had a febrile seizure. Thus, only 6/14 taking CBZ had a year completely seizure-free with no unacceptable medication side effects. Of those taking no medication, 2 had a febrile recurrence, and 7/17 had a year completely-seizure free. Side effects and febrile recurrences may limit the value of CBZ for some children, although CBZ appears to reduce significantly recurrences after a 1st afebrile seizure.